Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET
Soleno Therapeutics (NASDAQ: SLNO) has announced it will release its first quarter 2025 financial results and operational highlights after U.S. market close on Wednesday, May 7, 2025. The company will host its inaugural quarterly conference call and webcast at 4:30 PM ET on the same day.
The conference call will be accessible via U.S. toll-free number (1-800-717-1738), international number (1-646-307-1865), and Conference ID: 57643. A webcast replay will be available on the company's website for 30 days.
The PR also includes safety information for VYKAT XR, indicated for hyperphagia treatment in PWS patients aged 4 and older. Key safety considerations include contraindications for patients with hypersensitivity to diazoxide or thiazides, monitoring requirements for hyperglycemia, and risks of fluid overload. Common adverse reactions include hypertrichosis, edema, hyperglycemia, and rash.
Soleno Therapeutics (NASDAQ: SLNO) ha annunciato che pubblicherà i risultati finanziari e i principali aggiornamenti operativi del primo trimestre 2025 dopo la chiusura del mercato statunitense, mercoledì 7 maggio 2025. La società terrà la sua prima conference call trimestrale e webcast alle 16:30 ET dello stesso giorno.
La conference call sarà accessibile tramite numero verde USA (1-800-717-1738), numero internazionale (1-646-307-1865) e ID conferenza: 57643. La registrazione del webcast sarà disponibile sul sito web della società per 30 giorni.
Il comunicato stampa include anche informazioni sulla sicurezza di VYKAT XR, indicato per il trattamento dell'iperfagia nei pazienti con PWS di età pari o superiore a 4 anni. Le principali precauzioni di sicurezza riguardano le controindicazioni per i pazienti con ipersensibilità a diazossido o tiazidici, la necessità di monitorare l'iperglicemia e i rischi di sovraccarico di liquidi. Le reazioni avverse più comuni comprendono ipertricosi, edema, iperglicemia ed eruzione cutanea.
Soleno Therapeutics (NASDAQ: SLNO) ha anunciado que publicará sus resultados financieros y aspectos operativos del primer trimestre de 2025 después del cierre del mercado estadounidense, miércoles 7 de mayo de 2025. La compañía llevará a cabo su primera llamada de conferencia trimestral y webcast a las 4:30 PM ET del mismo día.
La llamada de conferencia será accesible mediante número gratuito en EE.UU. (1-800-717-1738), número internacional (1-646-307-1865) y ID de conferencia: 57643. La repetición del webcast estará disponible en el sitio web de la empresa durante 30 días.
El comunicado también incluye información de seguridad sobre VYKAT XR, indicado para el tratamiento de la hiperfagia en pacientes con PWS de 4 años en adelante. Las consideraciones clave de seguridad incluyen contraindicaciones para pacientes con hipersensibilidad a diazóxido o tiazidas, requisitos de monitoreo para hiperglucemia y riesgos de sobrecarga de líquidos. Las reacciones adversas comunes incluyen hipertricosis, edema, hiperglucemia y erupción cutánea.
Soleno Therapeutics (NASDAQ: SLNO)는 2025년 1분기 재무 결과 및 운영 주요 사항을 미국 시장 마감 후인 2025년 5월 7일 수요일에 발표할 예정입니다. 같은 날 오후 4시 30분(동부시간)에 첫 분기 컨퍼런스 콜 및 웹캐스트를 진행합니다.
컨퍼런스 콜은 미국 무료 전화번호(1-800-717-1738), 국제 전화번호(1-646-307-1865), 회의 ID: 57643를 통해 참여할 수 있습니다. 웹캐스트 녹화는 회사 웹사이트에서 30일간 제공됩니다.
보도자료에는 4세 이상 PWS 환자의 과식증 치료를 위한 VYKAT XR의 안전성 정보도 포함되어 있습니다. 주요 안전 고려사항으로는 디아조사이드 또는 티아지드에 대한 과민증 환자 금기, 고혈당 모니터링 필요성, 체액 과부하 위험이 있습니다. 흔한 부작용으로는 다모증, 부종, 고혈당, 발진 등이 있습니다.
Soleno Therapeutics (NASDAQ : SLNO) a annoncé qu'il publierait ses résultats financiers et faits marquants opérationnels du premier trimestre 2025 après la clôture du marché américain, le mercredi 7 mai 2025. La société tiendra sa première conférence téléphonique trimestrielle et webcast à 16h30 ET le même jour.
La conférence téléphonique sera accessible via un numéro gratuit aux États-Unis (1-800-717-1738), un numéro international (1-646-307-1865) et un ID de conférence : 57643. Le replay du webcast sera disponible sur le site internet de l'entreprise pendant 30 jours.
Le communiqué inclut également des informations de sécurité concernant VYKAT XR, indiqué pour le traitement de l'hyperphagie chez les patients PWS âgés de 4 ans et plus. Les principales précautions de sécurité comprennent les contre-indications chez les patients hypersensibles au diazoxide ou aux thiazidiques, les besoins de surveillance de l'hyperglycémie et les risques de surcharge liquidienne. Les effets indésirables courants incluent l'hypertrichose, l'œdème, l'hyperglycémie et les éruptions cutanées.
Soleno Therapeutics (NASDAQ: SLNO) hat angekündigt, seine Finanzergebnisse und operative Highlights für das erste Quartal 2025 nach Börsenschluss in den USA am Mittwoch, den 7. Mai 2025 zu veröffentlichen. Das Unternehmen wird am selben Tag um 16:30 Uhr ET seine erste Quartalskonferenzschaltung und Webcast abhalten.
Die Telefonkonferenz ist über die gebührenfreie US-Nummer (1-800-717-1738), die internationale Nummer (1-646-307-1865) und die Konferenz-ID: 57643 zugänglich. Eine Wiederholung des Webcasts wird für 30 Tage auf der Unternehmenswebseite verfügbar sein.
Die Pressemitteilung enthält auch Sicherheitsinformationen zu VYKAT XR, das für die Behandlung von Hyperphagie bei PWS-Patienten ab 4 Jahren zugelassen ist. Wichtige Sicherheitsaspekte umfassen Kontraindikationen bei Überempfindlichkeit gegen Diazoxid oder Thiazide, Überwachungsanforderungen bei Hyperglykämie und Risiken einer Flüssigkeitsüberladung. Häufige Nebenwirkungen sind Hypertrichose, Ödeme, Hyperglykämie und Hautausschlag.
- None.
- None.
REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, May 7, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information
| Date: | Wednesday, May 7, 2025 |
| Time: | 4:30 PM Eastern Time |
| United States: | 1-800-717-1738 |
| International: | 1-646-307-1865 |
| Conference ID: | 57643 |
| Webcast: | Link |
The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, www.soleno.life.
INDICATION
VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS).
IMPORTANT SAFETY INFORMATION
Contraindications
Use of VYKAT XR is contraindicated in patients who have a known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides.
Warnings and Precautions
Hyperglycemia
Hyperglycemia, including diabetic ketoacidosis, has been reported. Before initiating VYKAT XR, test fasting plasma glucose (FPG) and HbA1c; optimize blood glucose in patients who have hyperglycemia. During treatment, regularly monitor fasting glucose (FPG or fasting blood glucose) and HbA1c. Monitor fasting glucose more frequently during the first few weeks of treatment in patients with risk factors for hyperglycemia.
Risk of Fluid Overload
Edema, including severe reactions associated with fluid overload, has been reported. Monitor for signs or symptoms of edema or fluid overload. VYKAT XR has not been studied in patients with compromised cardiac reserve and should be used with caution in these patients.
Adverse Reactions
The most common adverse reactions (incidence ≥
Please see the full Prescribing Information, including Medication Guide.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s first commercial product, VYKATTM XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visit www.soleno.life.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those described in the company's prior press releases and in the periodic reports it files with the SEC. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
FAQ
When will Soleno Therapeutics (SLNO) report Q1 2025 earnings?
How can investors access SLNO's Q1 2025 earnings call?
What are the main safety concerns for Soleno's VYKAT XR medication?
What are the most common side effects of SLNO's VYKAT XR treatment?
